ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0479 • ACR Convergence 2024

    Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis

    Shant Ayanian, Collin Osborne, Marc Blasi, Daniel Darveaux, Eric Klee and Elena Myasoedova, Mayo Clinic, Rochester, MN

    Background/Purpose: Applying the methods of artificial intelligence (AI) to genomic data for clinical outcome prediction in rheumatoid arthritis (RA) is an area of growing research.…
  • Abstract Number: 0455 • ACR Convergence 2024

    Contraception Counseling for Patients with Rheumatic and Musculoskeletal Diseases (RMDs) at a Tertiary Care Rheumatology Clinic: A Quality Improvement Project

    Ikwinder Preet Kaur1, Gurjit Kaeley2, Cristine Arcilla3, Ngun Par4 and Thway Myant5, 1University of Florida College of Medicine, Jacksonville, FL, 2UF COM-J, Ponte Vedra Beach, FL, 3University of Florida Jacksonville, Jacksonville, FL, 4University of Florida Jacksonville Physicians Inc, Jacksonville, 5UF Jacksonville, Mia, FL

    Background/Purpose: RMD patients are at increased risk of adverse pregnancy outcomes either from the active disease itself or the use of immunosuppressants incompatible with pregnancy.…
  • Abstract Number: 0468 • ACR Convergence 2024

    Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks

    David Stevens1, Lene Sundbakk2, Amirhossein Kazemi2, Marte Heiberg3, Tuulikki Sokka-Isler4, Bjorn Gudbjornsson5, Kristina Lend6, Anna Rudin7, Michael Nurmohamed8, Jon Lampa9, Merete Hetland10, Mikkel Ostergaard11, Ronald Van Vollenhoven12, Tillmann Uhlig2, Espen Haavardsholm2 and Hilde Hammer3, 1St. Olavs hospital, Trondheim, Norway, 2Diakonhjemmet Hospital, Oslo, Norway, 3Diakonhjemmet Hospital, Oslo, Oslo, Norway, 4University of Eastern Finland, Faculty of Health Sciences, Jyvaskyla, Finland, 5Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, 6Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, 7Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, 8Amsterdam University Medical Centers, Amsterdam, Netherlands, 9Karolinska University Hospital, Hässelby, Sweden, 10Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, 11Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, 12Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands

    Background/Purpose: Plasma calprotectin is a sensitive biomarker of inflammation in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Calprotectin has not…
  • Abstract Number: 0457 • ACR Convergence 2024

    Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis

    Joshua Baker1, George Reed2, Geoffrey Thiele3, Dimitrios Pappas4, christina Charles-Schoeman5, Monica Guma6, Leslie Harrold7, Jeffrey Curtis8 and Joel Kremer9, 1Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, 2University of Massachusetts Chan Medical School, Worcester, MA, 3University of Nebraska Medical Center, Omaha, NE, 4CorEvitas, New York, NY, 5UCLA Medical Center, Santa Monica, CA, 6UCSD, La Jolla, CA, 7CorEvitas, Northborough, MA, 8University of Alabama at Birmingham, Hoover, AL, 9The Corrona Research Foundation, Delray Beach, FL

    Background/Purpose: While BMI has been associated with response to therapy in several studies in rheumatoid arthritis (RA), it is not a comprehensive measure of the…
  • Abstract Number: 0451 • ACR Convergence 2024

    Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome

    Juan J. Fierro1, Mirthe Schoots1, Silvia Liefers1, Berber Doornbos-van der Meer2, Gilles Diercks1, Hendrika Bootsma3, Jelmer R. Prins1, Johanna Westra1 and Karina de Leeuw4, 1University Medical Center Groningen, University of Groningen, Groningen, Groningen, Netherlands, 2University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 3Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 4University Medical Center Groningen, Groningen, Groningen, Netherlands

    Background/Purpose: SLE, primary Sjögren’s disease (pSjD) and APS are systemic rheumatic diseases (SRD) that mainly affect women of childbearing age and have been associated with…
  • Abstract Number: 0476 • ACR Convergence 2024

    Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study of 72 Patients

    Ana Serrano-Combarro1, Belén Atienza-Mateo2, Jesús Alejandro Valero Jaimes3, Marta Pastor-Mena4, Rafael Benito Melero-Gonzalez5, María Martín López6, Santos Castañeda7, Jesús Loarce8, César Antonio Egües Dubuc9, Natalia Mena Vázquez10, Carmen Carrasco-Cubero11, Carolina Perez-Garcia12, Juan M Blanco Madrigal13, Nuria Vegas Revenga14, Lorena Pérez Albadalejo15, Rafaela Ortega-Castro16, Desiree Palma17, Ana Fernández-Ortiz18, Maria López Lasanta19, Marta Garijo Bufort20, Ivette Casafont-Sole21, Andrea García-Valle22, Maria Paz Martinez-Vidal23, Bryan Josué Flores Robles24, EVELIN CERVANTES PEREZ25, Ignacio Brana Abascal26, Sara María Rojas Herrera27, Juan Camilo Sarmiento-Monroy28, Virginia Ruiz-Esquide29, JOSE RAMON LAMUA RIAZUELO30, Uxue Astigarraga-Urquia31, Diego Ferrer32 and Ricardo Blanco-Alonso33, 1Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Zumarraga Hospital, Zumarraga, Spain, 4Hospital de Jeréz de la Frontera, Cadiz, Spain, 5CHU Ourense, O Carballino, Spain, 6General University Hospital of Ciudad Real, Ciudad de México, Spain, 7Hospital Universitario de la Princesa, Madrid, Spain, 8Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 9Hospital Universitario de Donostia, Donostia, Pais Vasco, Spain, 10IBIMA, Málaga, Andalucia, Spain, 11Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 12Hospital del Mar, Barcelona, Spain, 13BASURTO UNIVERSITY HOSPITAL, Bilbao, Spain, 14Hospital Galdakao- Usansolo, Galdakao, Spain, 15Hospital Universitario de Jaén, Jaén, Spain, 16Hospital Reina Sofía, Cordoba, Andalucia, Spain, 17Hospital Rafael Méndez, Lorca, Murcia, Spain, 18Hospital Universitario de Badajoz, Badajoz, Spain, 19Hospital Vall d�Hebron, Barcelona, Spain, 20Hospital de Sagunto, Valencia, Spain, 21Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 22Hospital General Río Carrión, Palencia, Spain, 23Hospital San Juan de Alicante, Alicante, Spain, 24Hospital San Pedro, Logroño, Spain, 25Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, 26Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, 27Hospital de Mérida, Badajoz, Spain, 28Hospital Clínic Barcelona, Barcelona, Spain, 29Hospital Clinic de Barcelona, Barcelona, Spain, 30Hospital Universitario del Henares, Madrid, Spain, 31Hospital Universitario de Navarra, Pamplona, Spain, 32Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 33Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA) that determines a worse prognosis, leading the cause of mortality in RA…
  • Abstract Number: 0480 • ACR Convergence 2024

    Can’t Sleep, Won’t Sleep: A Systematic Review and Meta-Analysis of Insomnia Prevalence in 70,105 Rheumatoid Arthritis Patients

    Mohamed Abdelsalam1, Mamdouh Ahmed Khairy2, Mohamed Reda Awad3, Aly Alnabawy2, Maryam Taha4 and Mohamed Al-Adl Ali Ali2, 1Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, 2Faculty of medicine - Al-Azhar university Cairo branch, Cairo, Egypt, 3Al Azhar University, Cairo, Egypt, Giza, Egypt, 4Faculty of medicine - Ain Shams university, Madinat Nasr, Al Qahirah, Egypt

    Background/Purpose: Insomnia is a significant challenge for rheumatoid arthritis (RA) patients. Chronic pain conditions often exacerbate sleep disturbances, creating a vicious cycle where pain and…
  • Abstract Number: 0465 • ACR Convergence 2024

    Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays

    Monique Bastidas1, Lythou Yeo1, Susie Magpantay1, Judah Scott1, Mike Zikry1, Wayne Galdamez1, Jane Yang2 and Kelly Chun1, 1Labcorp, Calabasas, CA, 2LabCorp, Weston, MA

    Background/Purpose: Treatment of RA with biologic TNF inhibitors is effective in reducing disease activity and improving radiographic progression outcomes. Therapeutic drug monitoring (TDM) of adalimumab…
  • Abstract Number: 0488 • ACR Convergence 2024

    Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis

    Pablo Martínez Calabuig1, Elena Grau García2, Samuel Leal Rodriguez2, Ernesto Tovar Sugrañes3, José Ivorra-Cortés4, Carmen Riesco Barcena3, Anderson Huaylla Quispe3, Laura Mas Sánchez5, Pablo Muñoz Martínez6, Daniel Ramos Castro3, Alba Torrat noves7, Iago Alcantara Alvarez8, Belén Villanueva Mañés8, Miguel Simeo Vinaixa8, Andrés Pérez Hurtado3 and Jose A Román-Ivorra9, 1HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, 2HUP La Fe, Valencia, Spain, 3Rheumatology Department. HUP La Fe, Valencia, Spain, 4Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, 5Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, 6Hospital Universitario y Politècnico La Fe, Sagunto, Spain, 7Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, 8Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 9Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
  • Abstract Number: 0426 • ACR Convergence 2024

    Quality Improvement Initiative to Increase Contraception Screening and Documentation for Reproductive-Aged Women Prescribed Teratogenic Medications in an Academic Rheumatology Center

    Caroline Siegel1, Avi Mikhaylov1, Emily Wu2, Deanna Jannat-Khah1, Erika Abramson3, Lisa Sammaritano4 and Nancy Pan5, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Rochester, NY, 3Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, Scarsdale, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Rheumatology patients prescribed teratogenic medications often are not prescribed effective contraception. Efforts to improve this important quality indicator are limited by inadequate and poorly…
  • Abstract Number: 0303 • ACR Convergence 2024

    Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2

    Laura K. Ferris1, Jerry Bagel2, Yu-Huei Huang3, Andrew E. Pink4, Stephen K. Tyring5, Georgios Kokolakis6, Amy M. DeLozier7, Daniel Kakaley8, Shu Li9, Yaung-Kaung Shen10, Takayuki Ota7 and Robert Bissonnette11, 1University of Pittsburgh, Pittsburgh, PA, 2Psoriasis Treatment Center of Central NJ, East Windsor, NJ, 3Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), 4NHS Foundation Trust Great Maze Pond, London, United Kingdom, 5Center for Clinical Studies, Webster, TX, 6Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 7Janssen Research & Development, LLC, San Diego, CA, 8Janssen Scientific Affairs, LLC, Horsham, PA, 9Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, 10Janssen Research & Development, LLC, Spring House, PA, 11Innovaderm Research, Montreal, QC, Canada

    Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus…
  • Abstract Number: 0489 • ACR Convergence 2024

    Use of Chair Sit-to-Stand as a Pragmatic Alternative to Assess Frailty in Rheumatoid Arthritis

    Hannah Brubeck1, Kylie Riggles2, Riley Bass3, Elizabeth Wahl4, James Andrews5, Namrata Singh6, ariela orkaby7, Joshua Baker8, Patti Katz9, Dolores Shoback10, Jose Garcia11 and Katherine Wysham12, 1VA Puget Sound Health Care System, Seattle, WA, 2VA Puget Sound Health Care System, Bellevue, WA, 3VA Puget Sound Health Care System, Seattle, 4VA Puget Sound Healthcare System, Seattle, WA, 5University of Alabama at Birmingham, Birmingham, AL, 6University of Washington, Bellevue, WA, 7New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 8University of Pennsylvania, Philadelphia, PA, 9UCSF, San Rafael, CA, 10San Francisco VA/University of California, San Francisco, San Francisco, CA, 11VA Puget Sound Health Care System/University of Washington, Seattle, WA, 12VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA

    Background/Purpose: Frailty occurs earlier in people with rheumatoid arthritis (RA) than in the general population and is associated with poor health outcomes1, making it important…
  • Abstract Number: 0450 • ACR Convergence 2024

    Knowledge, Attitudes, and Intention Towards HPV Vaccination Among Reproductive-Age Women with Rheumatic Diseases

    Galilea Rodriguez1, Ana Rodriguez-Flores2, Mara Ponce3, Anahí Carrazco Chapa4, Karen Aglae Chavez-Olivo1, Aldo Patricio Romero-Avila1, Jesus Cardenas-de la Garza3, CASSANDRA SKINNER TAYLOR5, Lorena Perez-Barbosa6 and Dionicio Galarza-Delgado7, 1Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Mexico, 2Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 3Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 4Hospital Universitario Jose Eleuterio Gonzalez, UANL, Rheumatology, Monterrey, Mexico, Monterrey, Mexico, 5HOSPITAL UNIVERSITARIO DR JOSE ELEUTERIO GONZALEZ, MONTERREY, Mexico, 6Hospital Universitario, UANL, Monterrey, Mexico, 7UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Women with autoimmune rheumatic disease (ARDs) have a higher risk for cervical cancer due to the persistence of the HPV infection. HPV vaccination is…
  • Abstract Number: 0461 • ACR Convergence 2024

    Complete Description of the Three Pathways of the Complement System in a Series of 430 Patients with Rheumatoid Arthritis

    ivan Ferraz-Amaro1, Maria Garcia-Gonzalez2, Fuensanta Gomez-Bernal3, Juan Carlos Quevedo-Abeledo4 and Miguel Angel Gonzalez-Gay5, 1Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 3Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 4Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 5University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain

    Background/Purpose: The complement (C) system has been implicated in the etiopathogenesis of rheumatoid arthritis (RA). We aimed to examine the correlation between an in-depth evaluation…
  • Abstract Number: 0334 • ACR Convergence 2024

    Normal Creatine Kinase in Idiopathic Inflammatory Myopathies- Patient Characteristics and Disease Activity

    shiri keret1, Tanya Chandra2, Lisa Kaly3, Raisa Silva4, Eugenia Gkiaouraki5, Nantakarn Pongtarakulpanit6, shreya Sriram5, Rajesh Gopalarathinam7, Siamak Mogahadam6, Chester Oddis6 and Rohit Aggarwal8, 1Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, 2University of Pittsburgh Medical Center, Pittsburgh, PA, 3Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, 4Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Division of Rheumatology, Wrightington Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, United Kingdom, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: Creatine kinase (CK) is an important biomarker for the diagnosis and monitoring of Idiopathic Inflammatory Myopathies (IIM). However, in some cases, CK levels might…
  • « Previous Page
  • 1
  • …
  • 347
  • 348
  • 349
  • 350
  • 351
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology